Poor
Not Aligned
Patient Risk:
High
Summary
Only a subset of claims are supported by the provided label excerpts (e.g., hypertension indication, patch once every 7 days, and several mechanism/physiology statements). Many claims are not supported and key high-priority label safety domains (contraindications, boxed warnings, boxed warning applicability, comprehensive warnings/precautions, pregnancy/lactation, and pediatric safety) are not evaluated/covered.
Category Scores
Accurate Statements
Clonidine is used to treat high blood pressure.
INDICATIONS AND USAGE (p804122): clonidine transdermal system indicated for hypertension.
Clonidine stimulates alpha-adrenoreceptors in the brainstem and reduces sympathetic outflow.
CLINICAL PHARMACOLOGY (p537122).
Clonidine decreases heart rate.
CLINICAL PHARMACOLOGY (p537122) and (p543122).
Clonidine decreases blood pressure.
CLINICAL PHARMACOLOGY (p537122) and INDICATIONS AND USAGE (p804122).
Clonidine decreases peripheral resistance.
CLINICAL PHARMACOLOGY (p537122) and (p540122).
Clonidine transdermal patches are applied once every 7 days (weekly).
DOSAGE AND ADMINISTRATION (p3090122).
Unsupported Statements
Clonidine is prescribed for attention deficit hyperactivity disorder (ADHD).
No ADHD indication in the provided INDICATIONS AND USAGE excerpt.
Clonidine is prescribed for withdrawal symptoms from alcohol.
Not supported by the provided label excerpt(s).
Clonidine is prescribed for withdrawal symptoms from opioids.
Not supported by the provided label excerpt(s).
Clonidine is prescribed for withdrawal symptoms from smoking.
Not supported by the provided label excerpt(s).
Clonidine is available in oral tablet and transdermal patch formulations.
The provided label excerpts describe clonidine transdermal system; oral tablet availability is not supported in provided sections.
Clonidine oral tablets are typically taken multiple times a day.
No oral tablet dosing frequency is provided in the supplied label excerpts.
Clonidine patent expiration dates affect when generic versions can enter the market.
Not a prescribing-information claim supported by provided label excerpts.
Common side effects of clonidine include drowsiness.
The supplied excerpts mention drowsiness in OVERDOSAGE, not as a common adverse reaction.
Common side effects of clonidine include dizziness.
The excerpts discuss dizziness as a possible effect related to sedating drugs/orthostatic regulation; they do not support it as a 'common' side effect.
Common side effects of clonidine include dry mouth.
Not supported by provided label excerpts.
Common side effects of clonidine include constipation.
Not supported by provided label excerpts.
Common side effects of clonidine include fatigue.
Fatigue is mentioned in orthostatic regulation disturbances; 'common side effect' classification is not supported by provided excerpts.
Less common but more serious side effects of clonidine include changes in heart rhythm.
Dysrhythmias are described in OVERDOSAGE; 'less common' routine adverse reactions are not supported by provided excerpts.
Less common but more serious side effects of clonidine include low blood pressure.
Hypotension appears in OVERDOSAGE; 'less common' routine adverse reactions are not supported by provided excerpts.
Abruptly stopping clonidine can lead to withdrawal symptoms.
No provided label excerpt supports this statement.
Abruptly stopping clonidine can lead to a rebound increase in blood pressure.
No provided label excerpt supports this statement.
Abruptly stopping clonidine can be severe and even life-threatening.
No provided label excerpt supports this statement.
Clonidine should be tapered off gradually under medical supervision after stopping.
The provided excerpts advise avoiding interruption without physician’s advice and gradual reduction when substituting for other antihypertensives, but do not explicitly support tapering after stopping as stated.
Clonidine has been available as a generic medication for many years.
Not a prescribing-information claim supported by provided label excerpts.
Multiple pharmaceutical companies produce clonidine as a generic medication.
Not a prescribing-information claim supported by provided label excerpts.
Catapres (the original brand name for clonidine) was developed by Boehringer Ingelheim.
Not supported by provided label excerpts.
Clonidine is generally affordable as a widely available generic medication.
Not a prescribing-information claim supported by provided label excerpts.
For ADHD, clonidine is often used as an adjunct to stimulant medications.
Not supported by provided label excerpts.
For ADHD, clonidine is used as an alternative for individuals who cannot tolerate stimulants.
Not supported by provided label excerpts.
Stimulant medications like methylphenidate and amphetamines increase dopamine and norepinephrine levels in the brain.
Not supported by provided label excerpts for clonidine.
Clonidine primarily acts on alpha-2 adrenergic receptors.
Provided label excerpt states alpha-adrenoreceptors in brain stem but does not specify alpha-2.
Clonidine is sometimes used to manage physical symptoms of opioid withdrawal such as muscle aches.
Not supported by provided label excerpts.
Clonidine is sometimes used to manage physical symptoms of opioid withdrawal such as sweating.
Not supported by provided label excerpts.
Clonidine is sometimes used to manage physical symptoms of opioid withdrawal such as anxiety.
Not supported by provided label excerpts.
Clonidine does not directly treat opioid addiction.
Not supported by provided label excerpts.
Clonidine can make the opioid withdrawal process more manageable by reducing autonomic symptoms.
Not supported by provided label excerpts.
Contradictions
Low
AI Statement
Common side effects of clonidine include drowsiness.
Label Reference
OVERDOSAGE (p2859122) includes drowsiness as a toxicity sign/symptom; the claim categorizes it as a common side effect.
Important Omissions
Key safety label areas were not assessed/covered: contraindications, boxed warnings (if any), warnings/precautions, and safety monitoring elements (e.g., heart rate monitoring guidance).
Importance:
High
Specific-population safety statements (pediatric safety/effectiveness not established; nursing caution) were not evaluated against the provided excerpts.
Importance:
Moderate
Administration safety timing when substituting for oral clonidine/other antihypertensives (antihypertensive effect may not commence until 2–3 days) was not addressed as part of dosing/transition instructions.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Because many claims are not supported by the provided label excerpts and high-priority label safety domains (contraindications/boxed warnings/warnings/precautions and comprehensive safety language) were not evaluated, there is increased risk of mislabeling or omission of clinically important safety information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Moderate |
Recommendation
Not Aligned
Primary Issue
Multiple claims are absent from the provided FDA label excerpts (e.g., ADHD and multiple withdrawal indications) and the audit does not cover critical safety label domains (contraindications/boxed warnings/warnings/precautions and specific-population statements).
Suggested Improvement
Restrict claims to the provided label sections (e.g., hypertension indication for clonidine transdermal system) and add explicit auditing coverage for contraindications, boxed warnings, warnings/precautions, pediatric/nursing cautions, and administration/dosing transition instructions exactly as stated in the label.